Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism

Lung cancer is one of the leading causes of tumor-associated mortality, and >75% of patients with lung cancer have non-small cell lung cancer (NSCLC). Pemetrexed, a folate antagonist, is a first-line chemotherapy drug for NSCLC that is administered alone or in combination with cisplatin. The pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bo, Zhang, Junkai, Su, Ya, Hou, Yiling, Wang, Zhenguo, Zhao, Lin, Sun, Shengkai, Fu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755145/
https://www.ncbi.nlm.nih.gov/pubmed/31485626
http://dx.doi.org/10.3892/mmr.2019.10617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755145/
https://www.ncbi.nlm.nih.gov/pubmed/31485626
http://dx.doi.org/10.3892/mmr.2019.10617

Ejemplares similares